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Abstract
Background: Recent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that
tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of
AG490 on the development of T1D are unknown.
Materials and Methods: Female NOD mice were treated with AG490 (i.p, 1 mg/mouse) or DMSO starting at either 4 or 8
week of age, for five consecutive week, then once per week for 5 additional week. Analyses for the development and/or
reversal of diabetes, insulitis, adoptive transfer, and other mechanistic studies were performed.
Results: AG490 significantly inhibited the development of T1D (p=0.02, p=0.005; at two different time points).
Monotherapy of newly diagnosed diabetic NOD mice with AG490 markedly resulted in disease remission in treated animals
(n=23) in comparision to the absolute inability (0%; 0/10, p=0.003, Log-rank test) of DMSO and sustained eugluycemia was
maintained for several months following drug withdrawal. Interestingly, adoptive transfer of splenocytes from AG490
treated NOD mice failed to transfer diabetes to recipient NOD.Scid mice. CD4 T-cells as well as bone marrow derived
dendritic cells (BMDCs) from AG490 treated mice, showed higher expression of Foxp3 (p,0.004) and lower expression of co-
stimulatory molecules, respectively. Screening of the mouse immune response gene arrary indicates that expression of
costimulaotry molecule Ctla4 was upregulated in CD4+ T-cell in NOD mice treated with AG490, suggesting that AG490 is
not a negative regulator of the immune system.
Conclusion: The use of such agents, given their extensive safety profiles, provides a strong foundation for their translation
to humans with or at increased risk for the disease.
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Introduction
Tyrosine phosphorylation inhibitors, termed tyrphostins, are a
family of low molecular weight molecules having the ability to
inhibit tyrosine phosphorylation through protein tyrosine kinases
(PTKs). The family has at least 31 members, with AG490, also
known as tyrphostin B42, being one [1]. AG490 has been widely
studied in cancer and autoimmune diseases, but not subject to
investigation in the setting of T1D. Tyrosine kinase inhibitors
(TKIs) have been broadly used in many cancer clinical trials [2–4],
T1D [5,6] in mouse model of multiple sclerosis [7] and in
intestinal inflmmation is reported [8]. Oral administration of
Sunitinib (Sutent) and Imatinib (Gleevec), two TKIs, have been
shown to prevent and reverse T1D in the NOD mouse [5]. In
several publications successful remission of T1D has been reported
[9–16]; however, when it comes to monotherapy approach long-
lasting remission of diabetes is still challlenging [17].
The Jak-Stat signaling pathway plays a critical role in mediating
inflammatory immune response to a variety of signals [18–21].
Currently, several Jak-Stat inhibitors have been developed and are
under clinical investigation [4,22–25]. AG490 blocks the activa-
tion of the Jak and STAT family of molecules [1]. AG490 has been
reported to be more potent as a Jak2 inhibitor (4.3-fold) than Jak3
[26]; however, it has no impact on membrane associated kinases
such as Lyn, Btk, Syk, Src and Zap70 [27,28] suggesting that it is
not a general kinase inhibitor [26,27,29–31]. Additionally, AG490
blocks tumor growth and inhibits/delays the onset of autoimmune
diseases such as experimental autoimmune encephalomyelitis
(EAE) [32], inhibits antigen-specific T-cell infiltration in EAE
mice [32–34], and significantly extends rat heart allograft survival
[35]. AG490 also blocks IL-12 mediated T cell proliferation,
inhibits phosphorylation of Stat3, decreases IFN-c production
mediated by IL-12 [32], and inhibits differentiation of antigen-
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immunomodulating properties.
Previously, we reported several defects in the Jak-Stat5 signaling
pathway in NOD mice including autoactivation of Stat5, germ-
line mutation in Stat5B and impaired DNA binding of Stat5B in
NOD mice [37–39]. Given the influence of AG490 on the Jak-Stat
pathway, we sought to block the Jak-Stat signaling pathway and
investigate the effects of this compound on early (4weeks) and late
model of T1D development (8 weeks), insulitis and initiation of
remission of newly diagnosed and established diabetic NOD mice.
Results
AG490 prevents development of autoimmune diabetes
in NOD
Prediabetic female NOD mice were treated with AG490 (i.p,
1 mg/mouse) and control mice received the same volume of
vehicle (DMSO, solvent of AG490, and sterile PBS) three times/
week for 5 consecutive week and once a week for five more week
starting at 4 (preinsulitis) or 8 week of age (established insulitis).
Our data suggests that AG490 prevents development of autoim-
mune diabetes in NOD mice when applied at 4 or 8 week of age
(p=0.02 and p=0.005, respectively at week 30) (figure 1A & B).
Blood glucose and body weights (figure 1C and D) were monitored
in both groups as early as 6 week of age and continued for the
entire period of investigation. There was no statistically significant
differences in terms of body weights between AG490 and DMSO
treated mice suggesting administration of AG490 at the given dose
is safe in mice. Additionally, we also did not observe any adverse
effect of AG490 treated mice by gross examination suggesting that
efficacy and safety of multiple injections of AG490. This data
suggests that AG490 is an efficient and safe drug in prevention of
diabetes in NOD mice.
AG490 induces remission of autoimmune diabetes in
NOD mice
We sought to investigate whether AG490 would reverse
pathogenesis of T1D in newly diagnosed diabetic NOD mice.
Newly dignosed and established diabetic NOD mice were treated
with AG490 (i.p, 1 mg/mouse; no insulin was given to mice at any
time) and control group was treated with vehicle and blood glucose
was measured. Our data indicate that AG490 led significantly to
remission of diabetic mice (p=0.003, Log-rank test) while DMSO
treated control mice led to remission of 0% (n=10) (figure 2A &
B). Once euglycemia was established (Table S1), treatment was
ceased and normaglycemia lasts for several weeks and sustainable
euglycemia was maintained after drug withdrawal in majority of
the cured mice. These data suggest that NOD mice did not
develop resistance to AG490 treatment and additionally suggests
that AG490 has a durable effect on restoration of blood glucose
metabolism/regulation. However, diabetic NOD mice treated
with DMSO or left untreated expired within 2–4 weeks (figure 2B).
Average of blood glucose in the cured NOD mice at the disease
onset was 314.43 mg/dl (Max=374; Min=277 mg/dl) versus
384.58 mg/dl (Max=478, Min=335 mg/dl) (p,0.0014) in mice
that AG490 failed to restore euglycemia while an average blood
glucose in cure NOD mice was 169.82623.21 mg/dl versus
555.13663.79 (p=1.15E-11) in uncured NOD mice. This data
suggest that AG490 was more effective in diabetic mice with blood
glucose level ,314.43 mg/dl. A combination therapy, e.g
AG490+ insulin, may improve efficacy of AG490 treatment in
mice with blood glucose level .314.43 mg/dl.
AG490 treatment did not cause clinical signs of toxicity
and behavior
Treatment-related mortality in the course of i.p (intraperitoneal)
injection of AG490 and thereafter did not observe. Clinical signs of
toxicity related to treatment such as loss of body weight, strange
behavior such as aggressiveness, hypermobility, hunchback, and
other signs such as discoloration of the fur or fur loss, urine and
stool discoloration did not observed.Treatment did not change
apetite and food/water consumption as judged by body weight
gain/loss as measured 1–2 times per week and continued
throughtout the study and no differences between AG490 and
DMSO treated mice were observed (see figure 1C and D) owning
to the good general condition of animls. Laboratory examination
such as hematology, clinical chemistry and urine analysis did not
perform.
AG490 induces remission of diabetes in STZ induced
diabetic mice
To futher explore whether AG490 can reverse diabetes in STZ-
induced diabetic mice, BLAB/c mice were treated with STZ and
then were treated one week ater the last STZ injection either with
AG490 or DMSO (n=5/group). Our data indicate that the mean
blood glucose in DMSO treated mice was significantly higher than
AG490 treated mice after 2-weeks of treatment (DMSO:
498.6629.3 mg/dl; AG490: 240.4695.2 mg/dl; p,0.004)
(figure 2C & D). This data further suggests that AG490 is an
effective and safe drug to reverse onset of diabetes and further is
suggesting that the Jak-Stat signaling pathway may have additional
role(s) in pathogenesis of diabetes and on glucose metabolism than
currently appreciated.
Adoptive transfer of AG490 treated splenocytes did not
transfer diabetes in NOD.Scid mice
In order to understand how AG490 reversed and blocked the
onset of autoimmune diabetes in vivo, we treated prediabetic NOD
mice (4-week of age) with AG490 or with DMSO for 5 week. Mice
were sacrificied at week 10 and splenocyte cell suspensions were
prepared with Histopaque gradient separation. The dead cells and
reticulocytes were removed by the Histopaque gradient separa-
tion, therefore, dead cells were excluded without magnetic
purification and without activation of T-cells and cell viability
was greater than 99%. Five million freshely prepared of pooled
splenocytes of NOD mice treated with AG490 (n=5) or DMSO
(n=5) were transferred by i.p injection into recipient NOD.Scid
mice and blood glucose and body weight was closely monitored.
Our data as shown in figure 3 suggests that prevention of
autoimmune diabetes by AG490 could be due to inactivation of
atuoreactive T-cells and/or induction/generation of regulatory T-
cell or other regulatory population.
Administration of AG490 does not diminish leukocyte
infiltration within the pancreas
In another separate experiment, NOD mice at 4 week of age
were treated with AG490 or with DMSO (n=5/gorup), three
times per week for 5 consecutive week. Mice were sacrificed at
week 10 and microscopic sections were prepared and stained with
H & E and scoring of insulitis was performed as described in
materials and methods (figure 4A). There was no statistically
significance differences regarding insulitis between the two groups.
The C-peptide concentration was significantly different in AG490
treated versus DMSO treated mice (4 week group); however, no
significant differences in serum C-peptide concentration of AG490
or DMSO treated NOD mice (8 week group) was found (figure 4B).
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36079The C-peptide concentration of AG490 treated NOD (8 week
group) was significatly higher than the C-peptide level of mice
when treatment was initiated at 4 weeks of age. In a separate
experiment, female NOD mice were treated either with AG490 or
DMSO for 5 weeks and then were sacrificied at week 10. Total
RNA extracted from enriched infiltrating leukocytes from
Figure 1. AG490 prevents development of autoimmune diabetes. Prediabetic female NOD mice at 4 (UT: n=11; DMSO: n=13; and AG490
treated mice: n=15 mice/group) (A), or at 8 week of age, (n=10 per group) (B) were treated with AG490 or DMSO (i.p) for 5 consecutive week, three
time per week followed by once a week for 5 more week [Kaplan-Meier test (*p=0.02, 1A) and (**p=0.005, 1B, at week 30)]. Our data also indicate
that significant differences (p,0.01) was observed between the AG490 and DMSO treated mice for up week 52; when treatment was started at week
4. Body weight of NOD mice treated with AG490 (C) or DMSO (D) in mice when treatment initiated from 4 weeks of age is shown. [This figure is
intended to be in color online and black and white in print.]
doi:10.1371/journal.pone.0036079.g001
Figure 2. AG490 induces remission of diabetes in NOD and in STZ-induced diabetic mice. Newly diagnosed and established diabetic NOD
mice were treated with AG490 (i.p, 1 mg/mouse) without insulin supplement (A) (n=23) or with DMSO (B) (n=10). Blood glucose was measured by
ACCU-CHECK 2–3 times weekly. Sustainable euglycemia was observed for several months after drug withdrawal while DMSO treated mice expired
within 2–4 week after disease onset. The average blood glucose at the disease onset in the cured NOD mice was 314.43 mg/d (Max=374;
Min=277 mg/dl) versus 384.58 mg/dl (Max=478, Min=335 mg/dl) in mice that AG490 failed to restore euglycemia (p,0.0014). An average blood
glucose in cured NOD mice treated with AG490 was 169.82 mg/dl623.21, n=7 versus 555.13663.79, n=17 in uncured NOD mice (p=1.15E-11). (C)
Diabetes was induced by STZ injection in male BALB/c mice and one week after the last injection diabetic mice were treated with either AG490 or
DMSO (D) (n=5/group). The blood glucose level was significantly lower (p,0.004) in AG490 treated mice when compared with DMSO treated mice.
[This figure is intended to be in color online and black and white in print.]
doi:10.1371/journal.pone.0036079.g002
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was subjected to TaqMan Real-time RT-PCR. Level of Foxp3
and TGF-b1 expression were very low but detectable in AG940
treated NOD mice but we failed to detect expression of Foxp3 in
three independent RT-PCR in DMSO treated NOD mice
(figure 4C). This data suggests that although administration of
AG490 was unable to block infiltration of the leukocytes in the
islets or improve the C-peptide concentration; however, it changed
composition of the infiltrated leukocytes in the islets.
Administration of AG490 does not block expression of
Jak-1 and Stat-1 in leukocytes infiltrating the islets
Expression of the Jak and Stat family members in the islets of
NOD mice treated with AG490 or DMSO were screened by
immunofluorescen histochemistry technique. Expression of Jak3,
Stat3 and Stat5 was very low/undetectable in AG490 treated
mice. Expression of Jak2 was undetectable or it was very low even
in DMSO treated NOD mice. AG490 had no effect on
constitutive expression of the Jak1 and Stat1(figure S1). Higher
expression of Jak1 and Stat1 is of importance because it is known
that IFNc uses JAK-1 for activation of Stat1 [19,21,40].
Additionally, since adminsitration of AG490 might inhibit
expression of other kinases than members of the JAK family, we
screened expression of EGFR, c-Kit, PDGFR and c-Able by
western blot in splenocytes of NOD mice treated with AG490 or
DMSO (n=5). In several independent western blots, all detected
bands did not match with expected molecular weights of those
protein suggesting that expression of these kinases was very low
and AG490 likely does not have any impact on expression of these
kinases.
Administration of AG490 significantly increases
expression of Foxp3
To further understand as to whether AG490 prevented and
reversed diabetes in treated NOD mice, we measured expression
of Foxp3 and other regulatory markers by flow cytometry analysis
in different organs of the immune system in NOD mice that were
treated with either AG490 or DMSO. As shown in figure 5A–D
significant higher expression of CD25+Foxp3+ T-cells (p,0.004)
is evident in all organs tested in AG490 treated mice. Further-
more, AG490 treatment also increased expression of Foxp3 in
CD25+ T-cells in peripheral blood of the same groups of NOD
(Fig. 5E).
AG490 is not a negative regulator of the immune system;
screening of the mouse immune response genes array
In a separate experiment, pooled total RNA extracted from
purified CD4+ T-cells from spleen of the AG490 or DMSO
treated NOD mice (treated 3x/week for 5 weeks and euthanized at
week 10, n=5/group) were used to screen the mouse immune
response genes array (Applied Biosystems) by real-time TaqMan
Gene Expression RT-PCR. As shown in figure 5F, AG490 did not
negatively regulate overall gene expression of the mouse immune
response genes (see Table S2). Interestingly, in vivo treatment of
NOD mice with AG490 increased (2.15 fold) expression of co-
stimulatory Ctla4 in CD4+ T-cell. The Ctla4 gene is a diabetes
candidate gene for T1D and its association is well documented in
the literature [41–44]. Global gene expression screening from
different cellular component of the immune system of NOD mice
treated with AG490 is warranted to better understand mechanism
underlying modulatory function of AG490 and that may lead to
identify its target gene(s)/pathway(s).
In vivo and in vitro administration of AG490 modulates
phenotype and function of dendritic cells
Bone marrow of AG490 and DMSO treated NOD mice (4
weeks/3x/week, treated for 5 weeks) were harvested at week 10
and yeilded the same number of cells in each group (p=not
significant). We did not, however, notice any remarkable
difference in morphology, such as the size, shape and clonoy
formation, between the two groups in the course of differentiation
in cell culture. As shown in figure 6A and B, BMDCs (bone
marrow derived dendritic cells)of mice treated by AG490 had
markdly lower expression of co-stimualtory moelcules CD80 and
CD86 and adhesion molecule CD62L. Additionally, our real-time
TaqMan Gene expression Asssays (Assays-on-Demand) (Life
technologies, Applied Biosystems) indicates that AG490 signifi-
cantly increased expression of regulatory cytokine Tgf-b1i n
mature and immature DC (dendritic cell) when it was compared
with the sham treated control NOD mice (figure 6C, n=5/group,
p=0.02). Furthermore, BMDCs treated with AG490 (overnight,
20 mM) or DMSO suppressed proliferation of purified responding
CD4+CD252 T-cells in vitro (figure 6D).
Discussion
Presence of proinflammatory cytokines due to ongoing inflam-
mation in NOD mice, leads to autoactivation of different members
of the Jak and Stat family followed by activation of downstream
events as it has been reported by us [37,45] and others [46].
Recently, it has been shown that a transcriptomic analysis of
glomerular and tubulointerstitial tissues from diabetic subjects with
early and progressive diabetic nephropathy revealed involvement
of multiple members of the Jak/Stat signaling pathway [47].
Interestingly, higher expression of the Stat5B in progressive
diabetic nephropathy patients has been shown [47].
Tyrosine kinase inhibitors have been reported to decrease
insulin resistance [48] and increase insulin secretion in vitro [49,50].
In our study, AG490 decreased hyperglycemia in chemically
induced diabetic mice and in naturally developed diabetic NOD
mice. In chemically induced study, since the treatment with
AG490 was started one week after diabetes onset, beta-cell
Figure 3. In vivo AG490 treated splenocytes did not transfer
diabetes to NOD.Scid mice. Prediabetic NOD mice (4- weeks of age)
were treated with AG490 or DMSO for five consecutive week (n=5 per
group), three times per week and mice were sacrificed one week after
the last injection at week 10. Splenocyte cell suspension of pooled mice
immediately prepared and dead cells and red blood cells were removed
by Histopacque gradient separation method and freshly isolated
splenocytes containing .99% viable cells were transferred (5610
6,
i.p) into NOD.Scid mice. Blood glucose in recipient mice was monitored
at least once a week as described earlier (*: p=0.02, Kaplan-Meier test).
doi:10.1371/journal.pone.0036079.g003
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improvement in blood glucose level is the result of increased
insulin sensitivity by AG490. Rapid recovery from diabetes in
response to AG490 therapy, inefficiency of AG490 on the C-
peptide levels, the lack of any AG490 effect on leukocyte islet
infiltration- are all in agreement with improved insulin sensitivity
in peripheral target tissues. On the other hand, Real-time RT-
PCR data consistently indicates that expression of Foxp3 in
infiltrating lymphocytes in the pancreas of AG490 treated NOD
mice was detectable while it was undetectable in DMSO treated
mice (see figure 4C). This data suggests that AG490 treatment
changed composition of infiltrating leukocyte of the islet in NOD
mice.
Our previous reports regarding autoactivation and impaired
function of the Jak-Stat pathway [37,45] and our data in this
study-all may suggest that the Jak-Stat signaling pathway may be
Figure 4. AG490 does not block infiltration of leukocytes in the islets. A- Prediabetic NOD mice at 4 weeks of age were treated with AG490
or DMSO (n=5 per group) for 5 consecutive weeks (36per week) and mice were sacrificed one week after the last injection at week 10. Insulitis was
scored by two different investigators and an average of two different scores is shown (p=n.s). At least 150 islets per group in two interrupted
sections, 100 mm apart, was scored. B- The C-peptide level was measured as described in materials and methods and no significant differences were
found. C- Five prediabetic NOD mice at 4- weeks of age were treated with AG490 or DMSO (n=5 per group) as described above for 5 consecutive
weeks and then sacrificed at week 10, C- real-time RT-PCR was performed on enriched infiltrated lymphocyte from the pancreas of 5 mice/group and
expression level of Foxp3 and TGF-b1 was measured in three independent RT-PCR by TaqMan Gene expression (Life Technologies, Applied
Biosystems, Assays-on-Demand) (*=expression was very low and/or undetectable). [Figure 4A is intended to be in color online and black and white
in print.]
doi:10.1371/journal.pone.0036079.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36079an excellent target for immunotherapy of T1D and may also be
effective in type II diabetes, although this remains to be seen [51].
Autoactivation of kinases/transcription factors due to ongoing
autoimmunity will generate inflammatory cytokines which subse-
quently will lead to further inflammation. The Jak-Stat signaling
pathway is the most important signaling pathway for transduction
of signals from the cell surface to the nucleus [21,52–54]. This
signaling pathway is involved in the generation of pro-inflamma-
tory cytokines and is bound to have many more important roles in
the pathogenesis of T1D than currently is appreciated. Our study
uncovered several novel features of AG490 such as prevention of
diabetes, initiation of remission in newly diagnosed NOD mice
and in pharmacological induced diabetic mice, increasing number
of Foxp3 regulatory T-cells and probably generation of regulatory
DC. It is important to mention that significant differences
(p,0.01) in incidence of diabetes was observed between the
AG490 and DMSO treated mice for up to 52 week when
treatment was started at week 4. This data may suggest that
appropriate blocking of the Jak-Stat signaling pathway could bring
about a durable and long-lasting tolerance and further is
supporting the notion of safety and efficacy of AG490 in
prevention of autoimmune diabetes in NOD mouse.
Our data suggest that administration of AG490 blocks
expression of several members of the Jak and Stat families in
infiltrated leukocytes in the islets of NOD mice. Lack of the Stat3
expression is fatal perinataly [55], however, none of the treated
mice in this study died because of AG490 treatment suggesting
that treatment by AG490 was not life threatening. Our microarray
real-time TaqMan gene expression data suggests that AG490 may
exert its regulatory effect via upregulation of negative co-
stimulatory molecule, Ctla4, in CD4+ T-cells; however, additional
screening of different cellular component of the immune system is
warranted to identify it target gene(s)/pathway(s) and better
understand its molecular mechanism. Our data indicate that body
mass in AG490 and the sham treated control mice was not
significantly different from each other suggesting that AG490
treatment did not cause obesity [56].
In this study, we demonstrate that AG490 initiates remission of
diabetes in newly diagnosed and established diabetic mice, no
insulin was injected at any time, and sustained euglycemia was
evident for several months following drug withdrawal. It has been
shown that AG490 increased glucose uptake (10269) in L6
myotubes [48] under high glucose concentration in comparison
with vehicle-treated cells [57]. AG490 decreased fibronectin
expression; higher expression of fibronectin is associated with
nephropathy in diabetic subjects, under high glucose condition in
glomerular mesangial cell; therefore, AG490 potentially could be
an effective treatment for prevention of diabetic nephropathy [58].
Adoptive transfer of splenocytes isolated from in vivo treated mice
with AG490 failed to transfer diabetes to immunodeficient NOD
mice supporting the notion of inactivation of autoreactive T-cell or
induction of regulatory T-cell by AG490. DC plays a central role
in induction and maintenance of the central and peripheral
tolerance [59,60] and its development is impaired in NOD mice
[61]. As shown in this study, DC treated with AG490 possesses
regulatory function and suppress proliferation of responding T-
cells in vitro. Recently, Louvet et al have reported successful
reversal of diabetes by oral administration of tyrosine kinase
inhibitors [5], however, diabetes was transferred from drug and
the sham treated control mice into immunedeficient hosts with the
same kinetics [5] suggesting that induction of tolerance was
achieved by other means than generation of the regulatory T-cells.
In summary, this study provides evidence regarding application
of AG490 in prevention/reversal of autoimmune T1D in NOD
mouse. Administration of AG490 in vivo was very well tolerated
and treated NOD mice with AG490 showed no signs of toxicity
and they appeared healthier as they had a longer life span and
they were significantly diabetes-free when compared to the sham
treated or untouched control NOD mice. Additionally, this study
provides evidence regarding the crucial role of the Jak-Stat
signaling pathway in development of autoimmune diabetes and
regulation of blood glucose. Therefore, the Jak-Stat signaling
pathway may be an excellent pathway to be targeted for
immunotherapy and/or to reverse diabetes. The use of such
compounds like AG490, given their extensive safety profiles, offers
a solid foundation for their translation to diabetic subjects with or
at increased risk for the disease.
Materials and Methods
Ethics statement
All mice were maintained and handled in accordance with the
University of Florida Institutional Animal Care and Use Com-
mittee (IACUC), who specifically approved this study.
Mice
Female NOD/LtJ, NOD.Scid, and BALB/c mice were
purchased from Jackson Laboratories (Bar Harbor, ME) and
housed in ventilated cages in a specific pathogen free facility.
Compound
AG490 (EMD Chemicals, Gibbstown, NJ), 5 mg, initially was
dissolved in sterile DMSO (EMD Chemicals) and brought to final
volume by sterile PBS followed by several pipetting to bring the
compound into solution. One vial of compound containing 5 mg
of AG490 was injected into5 mice (1 mg/mouse) via the i.p route.
The control groups were received the same volume of the vehicle
under the same regimens and conditions.
Administration of AG490
Mice were injected either at 4 or 8 weeks of age, three times per
week for 5 consecutive weeks followed by 5 more injections, once a
week for 5 additional weeks. Body mass and blood glucose levels
were measured at the beginning of the study (baseline) and
Figure 5. AG490 upregulates expression of Foxp3 regulatory CD25+ T-cells in vivo. A- Prediabetic NOD mice (4 week) were treated either
with AG490 or DMSO three times per week for 5 consecutive weeks and they were sacrificed one week after the last injection at week 10. Data
represents pool cell suspensions of 5 NOD mice per group and is gated on live CD4+ T-cells. AG490 treatment significantly increases number of Foxp3
regulatory T-cells (p,0.004) (A–D). E- CD25+Foxp3+ gated population on CD4+ T-cell of several lymph nodes in AG490 and the sham treated control
NOD mice. Bars represent standard deviation of the mean. F- Whole blood of NOD mouse (pool of 5 mice/group) treated as described above was
stained directly with antibodies indicated as described in materials and methods. Data of gated CD4+ T-cells are shown. G- Total RNA from purified
CD4+ T-cells of splenocytes of NOD mice (10 weeks old) treated either with AG490 or DMSO from 5 weeks were subjected to real-time RT-PCR and
expression of the immune response genes was screened as described in materials and methods. Data shown is the mean of fold change expression of
18 genes after they were normalized based on expression of two housekeeping genes and then compared with the expression of the same gene in
DMSO treated control NOD mice. Spl=spleen, PLN=pancreatic lymph node, MLN=mesenteric lymph node, PP=Peyer’s patches, PB=peripheral
blood.
doi:10.1371/journal.pone.0036079.g005
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thereafter. Blood glucose concentrations were determined using
ACCU-CHEK Comfort Curve (Roche, Indianapolis), and diabe-
tes diagnosed if values were greater than 250 mg/dl in two
consecutive tests with 24 hours apart.
Figure 6. AG490 modulates phenotype and function of DC. A - Dendritic cells were generated from bone marrow of NOD mice treated either
with AG490 or DMSO as described in materials and methods and stained directly with CD11c, MHC II, CD80 and CD86. Data shown represents CD11c
gated population of pool fresh purified immature CD11c of AG490 and DMSO treated mice. B- Histograms represent expression of CD11c, CD86,
CD80 and CD62L on gated CD11c population of mice treated with AG490 or DMSO in vivo. C- Bone marrow cells were isolated from NOD mice
treated with AG490/DMSO for 5 weeks and then differentiated into DC in vitro as described. Total RNA (200 ng) of DC was converted into cDNA and
then expression of Tgf-b1 was measured by Real-Time TaqMan Gene expression assays (Applied Biosystems). Data represents the mean (fold change)
of two real-time RT-PCR experiments and the bars represent standard deviation of the mean. Fold change of Tgf-b1expression is shown (n=5 mice/
group, * p=0.02). D- BMDCs were generated from BALB/c mice treated in vitro with 20 mM AG490 or DMSO for 12 hrs and then co-cultured with
constant numbers of CD4+CD252 T-cells (1610
5) with soluble anti-CD3 (2.5 ng/ml) for 72 hrs. Incorporation of
3H-thymidine was measured in the
last 16 hr of cell culture. Experiment was performed in triplicate format and repeated at least twice. Data analysis was performed using the student t-
test and p value#0.05 considered significant. Bars represent deviation of the mean (* p=0.002, **p=0.0002; ***p=0.001). [Figures A & B are
intended to be in color online and black and white in print].
doi:10.1371/journal.pone.0036079.g006
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Clinical signs of toxicity related to treatment such as weight
gain/loss, abnormal behavior, discoloration of urine, stool and fur
monitored at least 3 times per week and continued throughout the
study. Body weight was recorded before initiation of the study and
measured 1–2 times weekly thereafter.
Induction of diabetes by i.p injection of streptozotocin
(STZ)
STZ (Sigma-Aldrich, St. Louis, MO) was freshly prepared in
citrate buffer (pH=4.5) just before injection and final volume was
adjusted by adding sterile PBS. BALB/c mice (n=10) were
received 5 dose of STZ (50 mg/kg) by i.p injection in 5-consecitive
days. Diabetic mice were treated one week post diabetes onset with
either AG490 or DMSO (control).
Purification of CD4+, CD4+CD25+/2 T-cells and dendritic
cells
Purification of CD4+CD25+ T-cells was performed from
pooled splenocytes using a CD4+CD25+ isolation kit (Miltenyi
Biotec, Auburn, AL) and autoMACS magnetic separator, accord-
ing to instructions provided by the manufacturer. Purity of purified
CD4+CD25+ and CD4+CD252 T-cells were greater than 85–
90% and 95%, respectively, as judged by flow cytometry analysis.
Splenic CD4+ T-cells and dendritic cells (from spleen and bone
marrow derived DCs) were enriched with CD4+ and CD11c
MicroBeads, respectively (Miltenyi Biotech) using autoMACS
instrument according to manufacturer’s instructions.
Generation of bone marrow-derived dendritic cells
Dendritic cells (DC) were generated from bone marrow in
5days. In brief, mice were euthanized and femur and tibiae
removed and cleaned from other tissues. Both ends of each bone
were cut and marrow flushed with RPMI 1640 containing 10%
serum. Red blood cells were lysed with an ammonium chloride
lysis solution (Sigma-Aldrich), and cells were plated at 1610
6 cells/
ml, 2 ml/well in 12-well plate (Falcon; BD Biosciences) in RPMI
1640 medium, supplemented with 1% penicillin and streptomycin,
10% heat-inactivated and filtered FCS containing rmGM-CSF
(500 U/ml R&D systems) and IL-4 (1000 U/ml, BD Biosciences).
On day 2, non-adherent and loosely adherent cells were harvested
by replacing one-half of the cell-containing supernatant from each
well and replaced with 1 ml of fresh medium containing cytokines.
On day 5, DC maturation proceeded by adding of LPS and those
cells that did not receive LPS were considered as immature DC.
Daily microscopic inspection of cell culture by microscopic
examination was performed until the end of the DC culture.
T- cell culture, Proliferation/Suppression assays
The AG490/DMSO treated bone marrow derived DC
(BMDC) were cultured at different ratios, with constant number
of CD4+CD252 T-cells (1610
5), in 96-well round bottom plates
containing soluble anti-CD3 (2.5 mg/ml) for 72 hourrs. Prolifer-
ation of responding populations were measured in the last
16 hours of cell culture by measuring
3H-thymidine incorporation
into the DNA using Scintillation Counter (Beckman).
TaqMan mouse Immune Response Array and Real-Time
TaqMan Gene expression analyses
Total RNA was extracted from CD4 and dendritic cells using
RNAeasy kit (QIAGEN). CD4+ T-cells was purified from 5
individual mice using mouse CD4+ T-cell isolation kit (Miltenyi
Biotech) followed by autoMACS separation according to the
manufacturer’s instructions. To screen the Taqman Array Mouse
Immune Response, 200 ng of total RNA was converted to cDNA
using High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). The cDNA from 5 mice were pooled together (one
microgram of total RNA) and then used to screen 96- immune
response related genes including 4 housekeeping genes. In the case
of Real-Time TaqMan Gene expression (Assay-On-Demand),
100 ng of total RNA was used for reverse transcription followed by
PCR amplification using 7300 Applied Biosystems PCR machine.
All primers and probes were purchased from Applied Biosystems
(Assays-on-Demand).
Adoptive transfer
Female NOD mice (4 weeks old) were treated with AG490 or
DMSO (n=5 per group) for 5 consecutive week, with three
injections per week. Mice were sacrificed one week after the last
injection (i.e., week 10). Cell suspensions of splenocytes from pool
mice were prepared, with dead cells and red blood cells removed by
Histopaque (Sigma) gradientseparation. Cell viability was .99% as
judged by trypan blue exclusion. 5610
6 splenocytes were
transferred by i.p injection into female NOD.Scid recipient mice.
Flow cytometry analysis
Cell surface staining was performed using anti-mouse CD4
(L3T4; BD Pharmingen, San Diego, CA), CD25 (3C7; BD
Pharmingen), CD11c (HL3; BD Pharmingen), CD80 (16-10A1;
eBioscience, San Diego, CA), biotin-conjugated MHC II (M5/
114.15.2; eBioscience) and anti-hTGFb- Biotin (BAF240; R & D
Systems) and biotin labeled anti chicken IgY (BAF010; R & D
System) for isotype control. Purified rat anti-mouse CD16/CD32
(2.4G2; BD Pharmingen) was used to block Fc receptor in myeloid
cell lineages. Intra-cellular staining of Foxp3 (FJK, 16S), IL-10
(JES5-16E3), IFNc (XMG1.2) was performed using Foxp3
intracellular staining kit (eBioscience), according to instructions
provided by the manufacturer. Viable cells were gated and a
minimum of 30,000 events were acquired using a FACScaliber
(BD Biosciences). Data was analyzed using FCS Express (v3)
software (De Novo Software, Los Angeles CA).
Histology and immunofluorescence histochemistry
(IFHC)
Pancreata were fixed in 4% PFA (paraformaldehyde) and
microscopic sections prepared with 100 mm interval from paraffin
embedded tissue, and stained with H & E, at the Pathology Core
Laboratories at University of Florida. Insulitis scoring was
performed in a blinded fashion. A numeric code was given to
each slide and then scored by two different investigators. A three
point scoring method was used where 0 was given to pre-insulitis
or intact islets, 1 was given to islets with ,50% infiltration and 2
where infiltration was .50%. IFHC was performed on 4 mm
paraffin sections of pancreas from the NOD mice. The concen-
tration of primary antibodies was based on recommendation of the
manufacturers. Stat1p91 (SC-591), Stat3 (SC-7179), Stat5B (SC-
835), IFNc (SC-8308), insulin (SC-7838), Jak1 (SC-277), JAk2 (SC-
1656), Jak3 (SC-6932), Tyk2 (SC-136265), were from Santa Cruz
(Santa Cruz, CA) and were diluted 1: 50 and TNFa-PE conjugated
Ab (Pharmingen) was diluted 1:100. Secondary fluorescence
conjugated antibodies with Alexa Fluor 488 (green) (1: 200) or
Alexa Fluor 594 (red) (1: 500) (Invitrogen, Carlsbad, CA) against
the host primary antibody were used for signal detection. Anti-fade
solution (Invitrogen) containing DAPI was used for counter
staining and mounting.
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mice treated either with DMSO or AG490 using RIPA lysis and
extraction buffer containing Halt Protease and phosphatase
inhibitor cocktail (Thermo Scientific). The following primary
antibodies were used in this study: anti- mouse CD140b
(PDGFRb), anti- mouse CD117 (c-kit) from eBioscience, and
anti-mouse Abe and EGFR (BD Bioscience), anti-phosphoPPARc
antibody (Millipore, Billerica), anti PPARc antibody (R & D
Systems), and HRP conjugated antibodies (Sigma) with ECL
detection kit (Millipore) were used for signal detection.
Statistical analysis
All analyses for statistical significance were performed using
Prism 5.0 software (GraphPad Software Inc, La Jolla, CA). The t-
tests used for comparison of the mean for two groups and statistical
comparison among different groups were performed using one-
way analysis of variance (ANOVA) with Tukey’s and/or Dunnett’s
post correction test for multiple comparisons, and/or for
comparison with a control group, respectively. The Real-Time
data (RQ values, fold change) was calculated using integrated SDS
software, V1.4.0 (Applied Biosystems) and as described elsewhere
[62]. The DCt for each treated samples was compared with the
mean DCt of control samples (unstimulated) using the relative
quantitation 2
2(DDCt) method as described elsewhere [62]. In vivo
data was analyzed using Kaplan-Meier test. A P value less than
0.05 was considered significant.
Supporting Information
Figure S1 The effects of AG490 on members of the Jak-
Stat in the pancreas. Prediabetic NOD mice (4 week) were
treated either with AG490 or DMSO three times per week for 5
consecutive weeks and were sacrificed one week after the last
injection at week 10. Pancreata were fixed and immunofluores-
cence staining was performed on microscopic slides as described in
materials and methods. At least 30 islets per marker per group
were analyzed.
(DOCX)
Table S1 AG490 reverses diabetes in NOD mice.
Reversal of diabetes was performed by administration of AG490
via i.p route. Recently diagnosed diabetic NOD mice (n=23) were
under AG490 treatment for a period of 21 weeks. The age of
disease onset, blood glucose level at disease onset and the mean of
blood glucose level after treatment and also total number of
AG490 injections are shown. Bold cases represent NOD mouse in
which AG490 was effective and successfully established euglyce-
mia (n=7). *=Represents the mean of the blood glucose level and
standard deviation of the mean in NOD mice from two weeks post
diabetes onset till the end of the therapy is shown (week 21).
(DOCX)
Table S2 The mouse immune response genes to AG490
treatment. Female NOD mice were treated with AG490 or
DMSO 3x/week for 5 consecutive weeks and then they were
sacrificed one week after the last injection at week 10. Total RNA of
purified CD4+ T-cells of splenocytes of treated mice and controls
were pooled together and then subjected to real-time RT PCR using
the mouse immune response genes array (Applied Biosystems)
following manufacturer’sinstructions.Data analyzingwasperformed
using integrated software based on expression of two housekeeping
genes and then calibrated based on the control mice (DMSO treated
mice). Shown represents fold change gene expression in AG490
treated NOD mice when compared with the sham treated mice.
(DOCX)
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